OTHER PUBLICATIONS

Hammarlund et al., "Multiple diagnostic techniques identify previously vaccinated individueals with protective immunity against monkeypox", Nature Medicine, vol. 11, No. 9, Sep. 2005, pp. 1005-1011

Herrera at al., "Functional analysis of vaccinia virus B5R protein: essential role in virus envelopment is independent of a large portion of the extracellular domain", J. Virology, Jan. 1998, vol. 72, No. 1, pp. 294-302.

Hooper et al., (Abstract P23-6) "DNA immunization with the vaccinia L1R and/or A33R genes", poster at meeting for American Society for Virology, Jul. 1998, p. 190.

Hooper et al., (Abstract W33-5) "DNA vaccination against poxviruses using combinations of IMV and EEV immunogens" poster at meeting for American Society for Virology, Jul. 2000, p. 113.

Hooper et al., "DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge", Virology 266, (2000), pp. 329-339.

Heraud, et al., "Subunit recombinant vaccine protects against monkeypox", J. Immunology, 2006, pp. 2552-2564.

Hooper et al., "Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox", J. Virology, May 2004, vol. 78, No. 9, pp. 4433-4443.

Hooper et al., "Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates", Virology 306 (2003), pp. 181-195

Hutin et al, "Outbreak of human monkeypox, Democratic Republic of Congo, 1996-1997", Emerging Infectious Diseases, vol. 7, No. 3, May-Jun. 2001, pp. 434-438.

Ichihashi et al, "Identification of a vaccinia virus penetration protein", Virology 202, 1994, pp. 834-843.

Ichihashi et al., "Neutralizing epitope on penetration protein of vaccinia virus", Virology 220, (1996), pp. 491-494.

Isaacs et al., "Characterization of a vaccinia virus-encoded 42-kilodalton Class I membrane glycoprotein component of the extracellular virus envelope", J. Virology, vol. 66, No. 12, Dec. 1992, pp. 7217-7224.

Kemper et al., "Expected adverse events in a mass smallpox vaccination campaign", Effective Clinical Practice, Mar./Apr. 2002, www. acponline.org/journals/ecp/marapr02/kemper.htm, 9 pages.

Kulesh et al., "Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the Roche LightCycler and the Cepheid Small Cycler platforms", J. Clinical Microbiology, Feb. 2004, vol. 42, No. 2, pp. 601-609.

Lai et al., "The purified 14-kilodalton envelope protein of vaccinia virus produced in *Escherichia coli* induces virus immunity in animals", J. Virology, Oct. 1991, vol. 65, No. 10, pp. 5631-5635.

Law and Smith, "Antibody neutralization of the extracellular enveloped form of vaccinia virus", Virology 280, 2001, pp. 132-142.

Lin et al., "Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo", J. Virology, Apr. 2000, vol. 74, No. 7, pp. 3353-3365.

Manischewitz et al., "Development of a novel vaccinia-neutralization assay based on reporter-gene expression", JID 2003:188 (Aug. 1), pp. 440-448.

Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", JID 1999:179 (suppl. 1) S235-9.

Mercer et al., "A novel strategy for determining protective antigens of the parapoxvirus, Orf virus", Virology 229, (1997), pp. 193-200.

Mercer et al. (Abstract from Medline), "Lack of cross-protection between vaccinia virus and orf virus in hysterectomy-procured, barrier-maintained lambs", PMID:7801537, Aug. 15, 1994 (4), pp. 373-282

Meyer et al., "Outbreakes of disease suspected of being due to human Monkeypox virus infection in the Democratic Republic of Congo in 2001", J. Clinical Microbiology, Aug. 2002, vol. 40, No. 8, pp. 2919-2921.

Meyer et al., "Identification of binding sites for neutralizing monoclonal antibodies on the 14-kDa fusion protein of orthopox viruses", Short Communication, Virology 200, pp. 778-783 (1994). CDC. 2001. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb.Mortal.Wkly.Rep. 50:1-26.

CDC. 2003. Multistate outbreak of monkeypox—Illinois, Indiana, and Wisconsin, 2003. Morb.Mortal.Wkly.Rep. 52:537-540.

Moller-Larsen et al., "Humoral and cell-mediated immune responses in humans before and after revaccination with Vaccinia Virus", Infection and Immunity, vol. 19, No. 1, Jan. 1978, pp. 34-39.

Moss, Bernard, "Poxviridae: The viruses and their replication." Chapter 83 in Fields Virology, Third edition, ed. B.N. Fields et al., Lippincott-Raven Publishers, Philadelphia. 1996. pp. 2637-2671.

Nalca, A., A. W. Rimoin, S. Bavari, and C. A. Whitehouse. 2005. "Reemergence of monkeypox: prevalence, diagnostics, and countermeasures." Clin.Infect.Dis. 41:1765-1771.

Osterhaus, A. D., C. A. van Baalen, R. A. Gruters, M. Schutten, C. H. Siebelink, E. G. Hulskotte, E. J. Tijhaar, R. E. Randall, G. van Amerongen, A. Fleuchaus, V. Erfle, and G. Sutter. 1999. "Vaccination with Rev and Tat against AIDS." Vaccine 17:2713-2714.

Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", Abstract from PubMed online database, 1 page, derived from J. Virol., 1985, 56(2):482-488. Rodriguez et al., "Mapping and mucletode sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein", J. Virology, Nov. 1987, pp. 3550-3554.

Rodriguez et al., "The vaccinia virus 14-kilodalton fusion protein forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene", J. Virology, Jun. 1993, vol. 67, No. 6, pp. 3435-3440.

Roper et al., "Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene", J. Virology, Jun. 1996, vol. 70, No. 6, pp. 3753-3762.

Saha et al., "BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties", In ICARIS 2004, LNCS 3239. G. Nicosia, V. Cutello, P. J. Bentley, and J. Timis, eds. Springer, pp. 197-204.

Sanchez et al., "Biochemical analysis of the secreted and virion glycoproteins of Ebola virus", J. Virology, Aug. 1998, vol. 72, pp. 6442-6447.

Sanderson et al., "Teh vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles", Abstract from PubMed, 1 page, derived from J. Gen. Virol, 2000. 81 Pt.1:47-58.

CDC. 2003. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. Morb.Mortal.Wkly.Rep. 52:282-284.

Smith, G. L. and M. Law. 2004. The exit of vaccinia virus from infected cells. Virus Res. 106:189-197.

Snyder, J. T., I. M. Belyakov, A. Dzutsev, F. Lemonnier, and J. A. Berzofsky. 2004. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+T-cell peptide epitope of vaccinia and variola viruses. J.Virol. 78:7052-7060.

Vazquez et al., "The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts wit the 21-kilodalton (A17L) virus membrane protein through a C-terminal alpha-helix", J. Virology, Dec. 1998, vol. 72, No. 12, pp. 10126-10137.

Vazquez etal, "Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus", J. virology, Nov. 1999, vol. 73, No. 11, pp. 9098-9109.

Volchkov et al., "The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses", FEBS Letters, vol. 305, No. 3, 1992, pp. 181-184.

Wilson et al., "Epitopes involved in antibody-mediated protection from Ebola virus", Science, Mar. 3, 2000, vol. 2878, pp. 1664-1666. Wolffe et al., "A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies", Virology 211, pp. 53-62 (1995).